In the midst of a psychopharmacology crisis, psychedelics have re-emerged as a potential gamechanger for combatting the mental health epidemic. The FDA has granted breakthrough therapy designation to specific development programs including MDMA for PTSD and psilocybin for depression. These programs all involve psychedelic-assisted psychotherapy (PAT), a bundled model that includes preparatory,...